Shares of Azenta, Inc. (NASDAQ:AZTA – Get Free Report) have received a consensus recommendation of “Hold” from the eight brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $39.50.
Several research analysts have recently issued reports on AZTA shares. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Needham & Company LLC lowered their target price on shares of Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, May 6th.
Get Our Latest Analysis on AZTA
Institutional Inflows and Outflows
Azenta Stock Up 0.8%
NASDAQ AZTA opened at $23.13 on Wednesday. Azenta has a 52 week low of $15.93 and a 52 week high of $41.73. The stock has a market capitalization of $1.07 billion, a PE ratio of -5.84 and a beta of 1.39. The firm has a 50 day moving average of $22.03 and a two-hundred day moving average of $27.94.
Azenta (NASDAQ:AZTA – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.16). Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The firm had revenue of $144.80 million for the quarter, compared to analyst estimates of $148.47 million. During the same quarter last year, the firm earned $0.01 EPS. The company’s revenue was up 1.4% on a year-over-year basis.
About Azenta
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Read More
- Five stocks we like better than Azenta
- Could a Tesla-SpaceX Merger Be Closer Than Investors Think?
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
